Samuel Whittle
Overview
Explore the profile of Samuel Whittle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saadat P, Bansback N, Falahee M, Hiligsmann M, Tugwell P, Buchbinder R, et al.
BMJ Open
. 2025 Jan;
15(1):e088267.
PMID: 39819933
Introduction: The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review...
2.
Mittinty M, Mittinty M, Buchbinder R, Lassere M, Chand V, Whittle S, et al.
J Rheumatol
. 2024 May;
51(9):862-869.
PMID: 38692667
Objective: Dyadic coping, the process of coping that transpires between couples challenged by one partner's illness, is an important predictor of disease adjustment and patient well-being. However, the extent of...
3.
Putman M, Sufka P, Whittle S, Robinson P
Lancet Rheumatol
. 2024 Jan;
2(6):e317-e318.
PMID: 38273591
No abstract available.
4.
Ng J, Jafarov T, Little C, Wang T, Ali A, Ma Y, et al.
Nat Commun
. 2023 Nov;
14(1):6909.
PMID: 37907525
Osteoarthritis (OA) is characterised by an irreversible degeneration of articular cartilage. Here we show that the BMP-antagonist Gremlin 1 (Grem1) marks a bipotent chondrogenic and osteogenic progenitor cell population within...
5.
Ng J, Jafarov T, Little C, Wang T, Ali A, Ma Y, et al.
bioRxiv
. 2023 Apr;
PMID: 37034712
Osteoarthritis (OA), which carries an enormous disease burden across the world, is characterised by irreversible degeneration of articular cartilage (AC), and subsequently bone. The cellular cause of OA is unknown....
6.
7.
Cheyne S, Fraile Navarro D, Hill K, McDonald S, Tunnicliffe D, White H, et al.
J Clin Epidemiol
. 2023 Jan;
155:84-96.
PMID: 36639038
Objectives: To introduce methods for living guidelines based on practical experiences by the Australian Living Evidence Consortium (ALEC), the National Institute of Health and Care Excellence (NICE), and the Infectious...
8.
Cheyne S, Fraile Navarro D, Buttery A, Chakraborty S, Crane O, Hill K, et al.
J Clin Epidemiol
. 2023 Jan;
155:73-83.
PMID: 36603743
Objectives: This article is part of a series on methods for living guidelines, consolidating practical experiences from developing living guidelines. It focuses on methods for identification, selection, and prioritization of...
9.
Quinlivan A, Lester S, Barrett C, Whittle S, Rowett D, Black R, et al.
Rheumatol Adv Pract
. 2022 Nov;
6(3):rkac099.
PMID: 36424984
Objectives: To investigate the knowledge and beliefs of Australian patients with inflammatory arthritis regarding biologic/targeted synthetic DMARDs (b/tsDMARDs) and biosimilars and their sources of information. Methods: Participants enrolled in the...
10.
Tsakas J, Liew D, Adams C, Hill C, Proudman S, Whittle S, et al.
BMC Rheumatol
. 2022 Oct;
6(1):59.
PMID: 36244979
Objectives: There is scant research about laboratory monitoring in people taking conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for rheumatic disease. Our objective was to conduct a scoping study to assess...